INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype characterized with aggressive clinical course that comprises a heterogeneous group of lymphomas in terms of morphology, immunophenotype and molecular abnormalities. 1 Currently, a standard first line treatment for this disease is immunochemotherapy, combination of the antiCD20 antibody rituximab with anthracycline based chemotherapy regimen.
groups and for treatment strategies to be stratified accordingly. A major step forward was the segregation of DLBCL into distinct subtypes based on gene expression profiling. Two main subgroups were identified that correspond to different stages of lymphocyte development: the germinal center B-cell (GCB)-like type showed a gene expression profile reminiscent of normal germinal center B cells, whereas the activated B-cell (ABC)-like type had a gene signature similar to that of activated peripheral blood B cells. A third intermediate group could not be allocated to either GCB or ABC type. The different gene expression patterns corresponded to different clinical outcomes. Several attempts have been made to substitute this gene expression-based classification by more routinely applicable methods. 2 This classification can be used to stratify chemotherapytreated patients into low-and high-risk groups and it has prognostic significance in response to chemotherapy, as the patients with the germinal center signature have a better survival compared with the activated B-cell signature. As immunohistochemical classification of cell of origin would be more practical than gene expressionbased methods, several attempts have been performed to identify the germinal center and non-germinal center subgroups of DLBCL by immunohistochemistry (IHC). 2 The most widely applied Hans algorithm based on immunostaining for B-cell lymphoma (BCL6), interferon regulatory factor-4/multiple myeloma-1(IRF4/MUM1), cluster of differentiation CD10, reproduces the gene expression-based classification, with a result of 87% for the GCB and 73% for the non-GCB phenotypes with a misclassification rate of 20%. 3 According to same studies, immunohistochemically defined germinal center patients have significantly better survival than the nongerminal center patients 3 ,when the patients are treated only with chemotherapy, whereas in other studies no differences in the survival rates have been seen in patients treated with immunochemotherapy, where rituximab is added to standard chemotherapy regiment CHOP. 4, 5 Further, recent results, obtained in the immunochemotherapy settings are inconsistent. Some studies found no significant correlation between the cell of origin and outcome in the patients treated with immunochemotherapy. 6, 7 Recently the results from one large prospective study published in Blood (2010), revealed the data from the RICOVER-60 trial of the German group-DSHNHL and indicated that immunoblastic morphology and not immunohistohemical features predict the outcome of the DLBL. 8 In order to investigate the prediction value of the immunoblastic morphology (IB) as a possible prognostic indicator for the outcome of our DLBL patient treated with the Rituximab (R)-CHOP regimen we conducted a retrospective study.
METHODS

Patients and treatments
Our study enrolled 192 DLBL patients diagnosed and treated at the University Clinic of Hematology, Skopje, Macedonia in the period between February 2002 and December 2007. They were all with CD20-positive aggressive BCLs and were assigned to 8 cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen. The median follow-up of the patient was 36 months. The study was conducted in accordance with the Helsinki declaration. The baseline clinical characteristics were collected and the risk stratification scoring performed applying the International Prognostic Index. 
Immunohistochemical stainings
Immunohistochemistry was performed at Institute of Pathology, Medical Faculty, Skopje, Macedonia. All tissue biopsies were fixed in 10% buffered formalin and were routinely processed and embedded in paraffin and 4-6 micm sections were cut and stain in hematoxylin and eosin (H&E). Immunohistochemistry was performed on 4-6 micm sections by using a streptavidin-biotin complex technique. The IHC panel consisted of antibodies against CD20, BCL2, BCL6, MUM1. The primary antibodies, suppliers, and staining conditions are listed in Table 1 . Subtyping followed the definitions of 2008 WHO classification. 10 Immunoreactivity was determined without any knowledge of the clinical data of the patients. Antigen expression was evaluated by assessing the percentage of immunoreactive tumor cells in 10% increments. The cases were subclassified by using the modified algorithm described by Hans et al (Figure 1 ). 3 For evaluation of BCL2, BCL6, MUM1 the staining was interpreted as positive if 30% or more of the tumor cells showed expression. Using the modified Hans algorithm the cases were assigned to immunoblastic group if BCL6 or MUM1 were positive or both MUM1 and BCL6 were positive, and if BCL2 alone or both MUM1 and BCL2 and BCL6 were positive the cases were assigned to DLBCL group. 
Statistical analyses
For statistical analysis we used X 2 test to compare characteristics of two subgroups of patients, mean age was compared with t-test. Overall survival was defined as the time from initial diagnosis to the date of death or last contact. Time to treatment failure was defined as the time from initial diagnosis to the date of disease progression, treatment discontinuation, or patient death. The log-rank test was used to compare the survival distributions. OS and TTF were estimated according to Kaplan-Meier. P values less than 0.05 were considered statistically significant. The analysis was conducted with Statistic7 for Window. Table 2 provides an overview regarding the clinical parameters of all 192 patients with DLBL (60 patients with tumor classified as Immunoblastic (IB) DLBL, and 132 patients with tumor classified as DLBL). The two groups were statistically comparable regarding the age, gender distributions and all others already established prognostic parameters as performance status, advanced IPI, albumin level except for the low IPI 0-2 which was statistically associated with the GCB group (p=.024) ( Figure 2 ). As can be seen 100% of tumor samples expressed CD20, 20.8% of the IB group were BCL2 positive, and 81% of DLBCL were positive for the same marker, 97.2% of the IB group were BCL6 positive, and 52.2 of were DLBCL positive for BCL6, 98% of the IB group were MUM1 positive, and 39% of DLBCL were positive for the same marker Immunohistochemical profile is presented on Figure 3 . 
RESULTS
Patient characteristics
DISCUSSION
The aim of this study was to investigate the prediction value of the immunoblastic morphology (IB) as a possible prognostic indicator for the outcome of our DLBL patient treated with the Rituximab (R)-CHOP regimen.
The immunoblastic morphology as an important risk factor has historic features, it has been described by Lennert a long time ago, and its negative prognostic impact of IB morphology in DLBCL has been recognized in 1997, 2002 in Non Hodgkin Lymphoma Classification Project.
In our study 192 patients were treated with 8 cycles of CHOP chemotherapy with rituximab. IB morphology of the tumor cells emerged as a significant adverse prognostic factor that retained its prognostic relevance even when the clinical IPI factors were included. The prognostic impact of IB morphology was prominent within the patients cohort treated with RCHOP. The widely used Hans classifier 3 based on CD10, BCL6, MUM1 assigns DLBCL into two subcategories, as germinal center B-cell Like (GCB) and non-GCB DLBL, failed to show prognostic significance in the patients treated with rituximab.
The gene expression-based distinction between GCB and non-GCB DLBL carried a prognostic impact in the CHOP treatment era. The IHC algorithms were developed to translate the complex and multigene expression in to more applicable standards to routine formalin-fixed, paraffin-embedded tumor tissues; results from retrospective analyses are contradictory. In the CHOP treatment era, Hans classifier, or modified version of it, predicted survival of DLBCL patients in some studied 3,11-14 , but not in others. 15, 16 But the results were contradictory in DLBCL patients treated with R-CHOP protocol. 14, 17, 18 Ott et al worked on this problem in line with previous reports on a negative prognostic impact of IB morphology, like large prospective DLBCL trial from CHOP treatment era-NHL-B1 and B2 by the DSHNHL. 19 They now proved the data that IB morphology carries important prognostic information but in R-CHOP treatment era. In some series IB morphology represent a negative prognostic factor. 20 The most widely used antigens in DLBCL are of minor value when it comes to risk assessment of DLBCL patients treated with R-CHOP. The expression levels of individual biomarkers by tumor cells such as BCL-2 and BCL-6 in line with previous studies 21, 22 , also provide important prognostic information in DLBCL. Different studies have yielded conflicting and inconclusive results, which probably reflect the heterogeneity of the disease and the various methods used. Overexpression of BCL-2 is a significant prognostic factor in non GCB lymphoma, more specifically we have found that rituximab overcome the adverse influence of BCL-2 overexpression on survival in non GCB DLBCL.
In the study published by Bernd et al for the German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) 19 , they correlated the morphological subtype and the immunohistochemical classifier proposed by Hans et al, and they found a significantly higher number of non-GCB type cases within the immunoblastic group than in the centroblastic group. However, since this correlation was not very strong, morphology apparently cannot be regarded as an adequate surrogate for immunophenotype, although it was obvious that both, morphology and immunophenotype are indicators of distinct tumor biology. This concept is also supported by gene expression studies in which a similar correlation between immunoblastic morphology and non-GCB molecular profile has been observed.
Bernd et al 19 for the German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) found that intensified therapy led to a significant improvement of the outcome in comparison to that obtained with the standard CHOP regimen. This effect is not, however, likely to be sufficient to explain why they could not confirm the prognostic value of the Hans classifier or other previously reported immunohistochemical markers.
The combination of the CHOP regimen with the monoclonal anti-CD20 antibody rituximab (R-CHOP) has considerably improved the outcome of patients with DLBCL. In this context, there is also some evidence to indicate that the impact of prognostic markers may be altered with the use of R-CHOP. The effect of rituximab does not, however, completely abolish the biological attributes of these lymphomas since at least some of the markers, for instance MHC class II gene expression, retain their prognostic value although the observable effects may be diminished.
Therefore, this study is suitable for identifying novel prognostic factor due to the high rate of events and concomitant high power. We presented our results on data sets including patients treated with rituximab with immunoblastic morphology with inferior survival comparing with other DLBL patients. Our study suggests in part new markers and that morphological subgrouping can be indicative of prognosis independently of IPI factors.
